Synthesis, cloning and expression of a novel pre-miniproinsulin analogue gene in Escherichia coli  by Abolliel, Ahmed A. & Zedan, Hamdallah
Journal of Advanced Research (2015) 6, 663–671Cairo University
Journal of Advanced ResearchORIGINAL ARTICLESynthesis, cloning and expression of a novel
pre-miniproinsulin analogue gene in Escherichia coli* Corresponding author. Tel.: +20 1000066561.
E-mail address: hhzedan@hotmail.com (H. Zedan).
Peer review under responsibility of Cairo University.
Production and hosting by Elsevier
2090-1232 ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.
http://dx.doi.org/10.1016/j.jare.2014.03.002Ahmed A. Abolliel a, Hamdallah Zedan b,*a Egyptian Company for Production of Vaccines, Sera and Drugs (VACSERA), Giza, Egypt
b Department of Microbiology and Immunology. Faculty of Pharmacy, Cairo University, EgyptA R T I C L E I N F O A B S T R A C TArticle history:
Received 30 November 2013
Received in revised form 27 February
2014
Accepted 1 March 2014






Codon adaptation indexIn the present study, a novel pre-miniproinsulin analogue was designed to have a short 9 residue
sequence replacing the 35 residue C-chain, one lysine and one arginine added to the C-terminus
of the B-chain in combination with glycine and arginine substitution at A21 and B29, respec-
tively, and a 16-residue fusion partner comprising the pentapeptide sequence (PSDKP) of the
N-terminus of human tumor necrosis factor-a (TNF-a), 6 histidine residues for Ni2+ chelated
afﬁnity puriﬁcation and a pentapeptide ending with methionine for ease of chemical cleavage
fused at the N-terminus. Homology modeling of the designed protein against miniproinsulin
(protein databank ﬁle 1 efeA) as a template showed that the distance between the a-carbons
of the C-terminus of the B-chain and the N-terminus of the A-chain did not change; the
root-mean-square deviation of the backbone atoms between the structures of modeled minipr-
oinsulin and miniproinsulin template was 0.000 A˚. DNA sequencing of the synthesized gene
showed 100% identity with theoretical sequence. The gene was constructed taking into account
the codon preference of Escherichia coli (CAI value 0.99) in order to increase the expression rate
of the DNA in the host strain. The designed gene was synthesized using DNA synthesis technol-
ogy and then cloned into the expression plasmid pET-24a(+) and propagated in E. coli strain
JM109. Gene expression was successful in two E. coli strains: namely JM109(DE3) and
BL21(DE3)pLysS. SDS–PAGE analysis was carried out to check protein size and to check
and optimize expression. Rapid screening and puriﬁcation of the resulting protein was carried
out by Ni–NTA technology. The identity of the expressed protein was veriﬁed by immunolog-
ical detection method of western blot using polyclonal rabbit antibody against insulin.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
With the advent of recombinant DNA technology, a large
number of recombinant proteins have been produced in differ-
ent host organisms. However, this ﬁeld is still of a very limited
application in Egypt. Egyptian industrial organizations inter-
ested in biological products still depend on imported ﬁnal bio-
technology products or imported recombinant raw materials
for local formulation. In best cases, few depend on imported
664 A.A. Abolliel and H. Zedanbiotechnology processes with the turnkey approach for tech-
nology transfer.
Recombinant insulin was the ﬁrst biopharmaceutical agent
approved for human use in 1982 [1–3] and its analogues were
among the ﬁrst engineered biopharmaceutical products [4–6].
It represents the essential treatment of all Type I and a consid-
erable number of Type II diabetes patients. Diabetes mellitus is
a signiﬁcant public health problem globally and in Egypt. In a
recent study it is estimated that 346 million people worldwide
have diabetes [7,8]. In Egypt 6.2% of males and 8.2% of fe-
males are diabetics with an average prevalence of 7.2% in both
sexes [8]. On the economic side, insulin annual consumption in
Egypt was estimated to be 33 million US dollars for retail mar-
ket in 2009 [9] and consequently 60–65 million dollars total
consumption.
Human insulin is a small protein molecule made up of two
separate polypeptide chains (A and B, consisting of 21 and 30
amino acids, respectively) linked together by two inter-chain
disulﬁde bridges and one intra-chain A disulﬁde bridge. Substi-
tutions occur at many positions of either chain without affect-
ing the bioactivity [10–12]. Although the amino acid sequence
of insulin varies among species, certain positions and regions
of the molecule are highly conserved including positions of
the 3 disulﬁde bonds, amino and carboxyl regions of the A
chain and hydrophobic residues in the carboxyl terminal
region of the B chain [10].
In the pancreas, these chains are ﬁrst synthesized as a sin-
gle-chain precursor called pre-proinsulin, which is sequentially
processed into proinsulin and ﬁnally into insulin. The pre-
proinsulin is made up of the A and B chains linked by a middle
peptide chain (C) made of 35 amino acids ﬂanked by two pairs
of basic amino acids, Arg Arg and Lys-Arg and preceded by a
24 residue N-signal peptide [10–12]. The signal peptide is ﬁrst
eliminated leading to the formation of proinsulin which under-
goes proteolytic cleavage to release C peptide and mature
insulin.
Using recombinant DNA technology, it is possible to pro-
duce human insulin biosynthetically and to modify the insulin
molecule for potential therapeutic and physiological advanta-
ges by altering its absorption characteristics to achieve near-
normal glucose levels. Recombinant DNA technology has pro-
vided rapid-acting and long-acting insulin analogues for the
treatment of diabetes mellitus, with an efﬁcacy and safety that
have improved the treatment for this disease. Long acting insu-
lin analogues, created via recombinant DNA technology, are
modiﬁed versions of human insulin that primarily alter the
duration of absorption of the molecule from site of injection.
In recombinant insulin glargine, two arginine molecules are
added at position B30 and asparagine is replaced by glycine
at position A21. In insulin detemir the amino acid threonine
in position B30 is removed and lysine at B29 is acylated with
a myristic fatty acid residue. In insulin degludec, a basal insulin
analogue with a potential of a thrice-weekly dosing schedule
currently in Phase III development, human insulin amino acid
sequence is retained but there is a deletion of threonine at B30
and addition of a 16-carbon fatty diacid attached to lysine at
B29 via a glutamic acid spacer [13].
However, concerns have been raised in connection with the
structural modiﬁcation of the insulin molecule. Increased bind-
ing afﬁnities to the insulin like growth factor 1 (IGF1) receptor
with potential for increased mitogenic action compared to hu-
man insulin has been reported [14–16]. Addition of positivelycharged basic arginine residues at position B31–32 of the C-
terminus of the B chain increases the afﬁnity for the IGF1
receptor [16]. This may potentially constitute a major health
problem, particularly with the long term dosages required
for diabetes mellitus patients. Development of new insulin ana-
logues devoid of the enhanced IGF-1 binding afﬁnity would
represent an attractive alternative. The increased IGF-1 afﬁn-
ity could be attenuated through the addition of a single argi-
nine to the C terminus of the B chain [15,16] or substitution
of one or both arginine residues with less positively charged
basic amino acids.
Recombinant human mini-proinsulin is a novel insulin pre-
cursor with a shortened C-peptide chain which could be easily
converted by enzymatic cleavage into human insulin [10]. Re-
cently, a number of mini proinsulins with various mini C-pep-
tides were produced to increase the folding efﬁciency of the
insulin precursor and the production yield of insulin [10,17,18].
In the present study, a gene coding for a novel pre-minipr-
oinsulin analogue with a potential industrial application for re-
combinant human insulin production was synthesized using
DNA technology, cloned in a suitable expression vector and
expressed in a selected Escherichia coli strain. SDS–PAGE
analysis was used to detect the expressed protein and to eval-
uate the efﬁciency of the used expression system.
Material and methods
The expression vector pET-24a(+) was obtained from Nova-
gen and the pMA-PMPA plasmid (a pMA plasmid harboring
Pre-miniproAbollien gene) from Geneart, Germany. Restric-
tion enzymes, T4 DNA ligase, kits for DNA gel extraction
and puriﬁcation and kits for plasmid extraction and puriﬁca-
tion were purchased from Promega, USA. Protein puriﬁcation
Ni–NTA Spin Kit was purchased from Qiagen, Germany.
E. coli host strains JM109 (Genotype: endA1, recA1, gyrA96,
thi, hsdR17 (rk, mk+), relA1, supE44, D(lac-proAB), [F0
traD36, proAB, laqIqZDM15]), JM109(DE3) (Genotype:
endA1, recA1, gyrA96, thi, hsdR17 (rk, mk+), relA1,
supE44, k, D(lac-proAB), [F0, traD36, proAB, lacIqZDM15],
kDE3) and BL21(DE3)pLysS (Genotype: F, ompT, hsdSB
(rB, mB), dcm, gal, k(DE3), pLysS, Cmr) were obtained
from Qiagen, Germany. Designed gene was synthesized and
optimized in Geneart, Germany. Forward and reverse T7 pro-
moter primer and T7 terminator primer were synthesized by
Operon Company, France.
Design of pre-miniproinsulin analogue
A new basal pre-miniproinsulin analogue was designed by
making three modiﬁcations in the structure of a human
miniproinsulin template (protein databank ﬁle 1efeA): inclu-
sion of a pre-area consisting of a fusion partner (N-terminal
pentapeptide sequence (PSDKP) of human tumor necrosis fac-
tor-a, TNF-a), a spacer (six histidine residues) and ﬁve peptide
sequence ending by methionine (Ser-Ser-Gly-Ser-Met);
replacement of the 35-residue C-peptide with 9 residues (Lys-
Arg-Tyr-Pro-Gly-Asp-Val-Lys-Arg) as mini turn forming se-
quence; and change in the insulin chains by the addition of
one lysine at B31 and one arginine at B32 of the C-terminus
of the B-chain in combination replacement of asparagine at
A21 with glycine and of lysine at B29 by arginine. The ﬁnal
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resulting analogue was named Abollien.
Homology modeling of the designed miniproAbollien using
miniproinsulin (protein databank ﬁle 1efeA) as a template was
done by DeepView/Swiss-Pdb Viewer. Target-template align-
ment and model construction were carried out. After optimiza-
tion the distance between the a-carbons of the C-terminal of
the B-chain and the N-terminal of the A-chain was measured.
Model quality assessment was done by calculating the
root-mean-square deviation of the backbone atoms (240
atoms) between the structures of modeled miniproAbollien
and miniproinsulin, search residues making clash generally
or with backbone and search for threading energy high values.
A gene coding for Pre-miniproAbollien (231 bp not includ-
ing restriction sites) was optimized for expression in E. coli
using GeneOptimizer at Geneart to select the proper codons
to be used during translation of amino acid sequence to codon
sequence. It was then synthesized by DNA synthesis technol-
ogy ﬂanked by two restriction sites NdeI and XhoI at 50 end
and 30 end respectively. The fragment was cloned into pMA-
plasmid (ampR) to form the construct pMA-PMPA. The ﬁnal
construct was veriﬁed by DNA sequencing then alignment
against original DNA sequence using multiple-alignment algo-
rithm in Megallign (DNASTAR, Window version 3.12e). The
construct was then lyophilized.Gene sub-cloning
Sub-cloning strategy depended on directional cloning to de-
crease background of self-ligated vector and prevent inverted
orientation insert [19]. E. coli strain JM109 was chosen for
sub-cloning to stabilize insert and prevent restriction of con-
struct and protect it to be able to transform wild type rþk
E. coli strains. Reconstituted pMA plasmid harboring Pre-
miniproAbollien gene (pMA-PMPA) was transformed into
E. coli JM109 competent cells according to the method of
Chung et al. [20]. The cells were then spread over SOB media
plates containing 1% glucose and 100 lg/ml ampicillin and
incubated overnight at 37 C. Transformed cells were then
used to propagate pMA-PMPA plasmid. Propagated pMA-
PMPA plasmid was extracted and puriﬁed from the trans-
formed cells using plasmid extraction kit, and a sample of
the puriﬁed propagated pMA-PMPA plasmid was also loaded
to 1% agarose gel to check concentration against a pMA-
PMPA standard solution. Double restriction digestion of
pMA-PMPA was carried out using restriction enzymes NdeI
and XhoI and the insert was then separated by agarose gel
electrophoresis. The insert gel slices were cut and the insert
was puriﬁed using DNA gel extraction and puriﬁcation kit.
The puriﬁed insert was then loaded onto 2% agarose gel to
determine its concentration.
For linear vector preparation, reconstituted pET-24a(+)
plasmid was transformed into E. coli JM109 competent cells
according to the method described by Chung et al. [20]. The
cells were then spread over the surface of SOB media plates
containing 1% glucose and 30 lg/ml kanamycin and incubated
overnight at 37 C. Transformed cells were then used to prop-
agate pET-24a(+) plasmid. Propagated pET-24a(+) plasmid
vector was extracted and puriﬁed from the transformed cells
using plasmid extraction kit, and a sample of the puriﬁed prop-
agated pET-24a(+) plasmid vector was loaded to 0.8%agarose gel to check its concentration against pET-24a(+)
standard solution. Double restriction digestion of pET-
24a(+) plasmid vector was done using restriction enzymes
NdeI and XhoI in order to get a to linear vector. The linear
vector was then separated by agarose gel electrophoresis.
The linear vector gel slices were cut and puriﬁed and sample
of the puriﬁed linear vector was loaded to 0.8% agarose gel
to determine its concentration.
The expression construct (pPMPA) was prepared by liga-
tion of puriﬁed Pre-miniproAbollien insert and puriﬁed linear
pET-24a(+) plasmid vector using T4 DNA ligase. The ligation
reaction was used to transform E. coli JM109 competent cells
and the cells were then spread over SOB media plate contain-
ing 1% glucose and 30 lg/ml kanamycin and incubated over-
night at 37 C. Transformed cells were used to propagate
expression construct (pPMPA).
The propagated expression construct was extracted and
puriﬁed from E. coli JM109 transformed cells by plasmid
extraction and puriﬁcation kit. The puriﬁed expression con-
struct was checked by performing PCR reaction to amplify
the fragment comprising the site of cloning of Pre-minipro-
Abollien using T7 promoter primer and T7 terminator primer
then run on agarose gel to check its base pair number (theoret-
ically to be 423 bp while that of plain pET-24a(+) is 255 bp).
The puriﬁed expression construct pPMPA was used to
transform two bacterial expression strains E. coli JM109(DE3)
and E. coli BL21(DE3)pLysS. Control experiments were done
for each expression strain. E. coli JM109(DE3) competent cells
transformed with pPMPA were spread over a SOB media plate
containing 1% glucose and 30 lg/ml kanamycin; sufﬁcient
number of separated colonies was obtained after incubation
overnight at 37 C. Similarly, E. coli BL21(DE3)pLysS compe-
tent cells transformed with pPMPA were spread over a SOB
media plate containing 1% glucose, 30 lg/ml kanamycin and
34 lg/ml chloramphenicol. It showed growth of sufﬁcient
number of separated colonies after incubation overnight at
37 C.
The expression construct was extracted from each strain
and puriﬁed by plasmid extraction and puriﬁcation kit for ver-
iﬁcation. Each puriﬁed construct was checked by performing
PCR reaction to amplify the fragment comprising the site of
cloning of Pre-miniproAbollien then run on agarose gel to
check its base pair number (which is different from plain
pET-24 a(+)) against DNA ladder. After the gel was exam-
ined using Fotodyne UV transilluminator (Foto/UV 15) bands
were excised and the expression construct from each strain was
extracted and puriﬁed by the gel extraction kit and then sent
for sequencing and the two sequences were aligned to theoret-
ical sequence.Expression of recombinant Pre-miniproAbollien analogue
A loopful from a glycerol stock of E. coli JM109(DE3) expres-
sion strain transformed with pPMPA was streaked on SOB
media plates containing 1% glucose and 30 lg/ml kanamycin
under Laminar Air Flow (LAF) cabinet and a loopful from
a glycerol stock of E. coli BL21(DE3)pLysS expression strain
transformed with pPMPA was streaked on SOB media plates
containing 1% glucose and 30 lg/ml kanamycin and 34 lg/ml
chloramphenicol. The plates were incubated inverted at
37 C overnight. One of the transformed E. coli JM109(DE3)
666 A.A. Abolliel and H. Zedangrown colonies was used to inoculate 10 ml LB broth contain-
ing 1% glucose and 30 lg/ml kanamycin and E. coli
BL21(DE3)pLysS transformed cells was inoculated into
10 ml LB broth containing 1% glucose and 30 lg/ml kanamy-
cin and 34 lg/ml chloramphenicol and incubated overnight at
37 C with shaking at 225 rpm. Two ml of each of the over-
night cultures was centrifuged at 1000g for 5 min and the cells
were then resuspended in new media with same overnight med-
ia compositions and immediately used to inoculate 50 ml of LB
broth containing 1% glucose and 30 lg/ml kanamycin in case
of E. coli JM109 (DE3) and in 50 ml LB broth containing 1%
glucose and 30 lg/ml kanamycin and 34 lg/ml chlorampheni-
col in case of E. coli BL21(DE3)pLysS. The inoculated broth
was incubated at 37 C with shaking at 300 rpm until the opti-
cal density of the broth (measured at 600 nm) was between 0.6
and 0.9. Induction was then done by adding 500 ll of sterile
100 mM IPTG to each culture. A negative control for each
strain with pET 24a(+) transformed cells were treated exactly
the same for each strain. One ml sample was taken from each
expression strain just before induction and at 1, 2, 4, 6 and 8 h
after induction respectively.
Samples from E. coli expression cultures were loaded onto
One-dimensional gel electrophoresis under denaturing condi-
tions to check the whole cell lysates including the expressed
protein. The expressed protein was lower than 10 kDa (average
molecular weight 8.4 kDa). Gel preparation and running were
done using Nonurea peptide separations with tris buffers
method comprising the traditional Laemmli buffer system with
slight modiﬁcation [21]. Gel preparation, staining and de-stain-
ing were done according to Coligan [22].
For rapid screening and puriﬁcation, expression of Pre-
miniproAbollien in E. coli JM109(DE3) was done according
to previously described methods except that 4 h after the
OD600 had reached 0.8, 40 ml of the culture was harvested by
centrifugation. The resulting pellet was freezed by liquid nitro-
gen and stored at 20 C. The cells (pellet) were thawed for
15 min and resuspended in 4 ml Buffer (8 M urea; 0.1 M NaH2-
PO4; 0.01 M TrisÆCl; pH 8.0) and incubated with shaking for
1 h at room temperature. Cells lysate was centrifuged at
10,000g for 20–30 min at room temperature. The supernatant
(cleared cell lysate) was collected to be puriﬁed and a sample
of it was saved for SDS–PAGE analysis. Puriﬁcation of Pre-
miniproAbollien from the cleared cell lysate was done using
Ni–NTA Spin Kit according to the manufacturer’s instructions
[23]. Puriﬁcation depended on the interaction of six histidine
amino acids in the pre area of Pre-miniproAbollien and immo-
bilized nickel ions held to the NTA resin in the kit columns.
Immunological detection of Pre-miniproAbollien by wes-
tern blot using polyclonal rabbit antibody against insulin was
carried out to check the identity of the expressed protein.
New two parallel SDS–PAGE’s were done as previously
described. Each gel was loaded with 10 ll and 20 ll of puriﬁed
Pre-miniproAbollien using prestained Pierce blue protein
molecular weight as protein marker. After the end of the gel
running one gel was stained and the second gel was transferred
to nitrocellulose membrane according to the method described
by Coligan [22]; the membrane was then cut into two strips, one
strip was stained with Coomassie blue and the other was stored
at20 C until used in immunoblotting. Antibodies against hu-
man insulin (prepared in a healthy male New Zealand rabbit
according to Hu et al. [24]) were diluted (1:50) in PBS–0.3%
Tween 80 solution containing 5% nonfat dry milk and thenthe membrane strip containing Pre-miniproAbollien were im-
mersed in it and incubated for one hour on the shaker platform.
The strips were then washed 4 times (1 min for each washing)
with hot PBS/Tween 80. Goat anti-rabbit IgG labeled with per-
oxidase conjugate was used as 1/500 in 1· PBS–0.3% Tween to
cover the strip for 1 h at room temperature. This was followed
by washing 3 times with PBS/Tween 80 and twice with 1· PBS.
The substrate [(0.5 ml from 5% DAB) in (50 ml PBS + 5 ll
30% H2O2)] was used to cover the strip with shaking until
the color was developed. The reaction was stopped by washing
the membrane strip with distilled H2O [25].
Results
Design of Pre-miniproAbollien
The homologymodeling ofminiproAbollien using protein data-
bank ﬁle 1efeA referring tominiproinsulin as a template done by
DeepView/Swiss-Pdb Viewer (Fig. 1) showed that the distance
between the a-carbons of the C-terminal of the B-chain and
the N-terminal of the A-chain was the same (11.01 A˚) and the
root-mean-square deviation of the backbone atoms (240 atoms)
between the structures of modeledminiproAbollien andminipr-
oinsulin was 0.000 A˚. Threading energy did not show high val-
ues on the changed residues and there was no signiﬁcant
structural constraints on the remaining parts of the miniproin-
sulin. There were no residues making clash generally or with
backbone. All previous homology modeling checks indicated
that the small b turn and the changes in the chains do not affect
the three dimensional structure of miniproinsulin.
Sequencing of the synthesized Pre-miniproAbollien gene
showed 100% identity with theoretical sequence. The codon
adaptation index (CAI) value was 0.99 which means that co-
dons used in the optimized gene was near 100% of best choice
of codon preference in E. coli.
Cloning and expression of Pre-miniproAbollien
Expression construct was prepared by ligation and then trans-
formed into E. coli JM109 competent cells. The puriﬁed con-
struct was checked by amplifying the fragment comprising
the site of cloning of Pre-miniproAbollien using PCR and then
loaded into 2% gel. As shown in Figs. 2a and 2b, strong band
on 423 bp was observed on the construct lane; sample from
multiple cloning site in plain pET-24a(+) showed strong band
on 255 bp (as expected) and negative control showed no bands.
Puriﬁed construct was used to transform two E. coli expres-
sion strains E. coli JM109(DE3) and BL21(DE3)pLysS har-
boring a chromosomal copy of the bacteriophage T7 RNA
polymerase. Construct was retested after transformation into
expression strains in the same way as tested after transforma-
tion into E. coli JM109 and results are shown in Figs. 2a and
2b. Sequencing of the ampliﬁed fragment showed 100% iden-
tity with the theoretical sequence.
Expression cultures were sampled just before induction and
at 1, 2, 4, 6 and 8 h after induction with the synthetic lactose
analogue isopropyl-B-D-thiogalactopyranoside (IPTG) and
those samples were loaded to denaturing SDS discontinuous
gel. Stained gel showed distinct bands of intensity increasing
with time between 7 and 15 kDa (expected molecular weight
of Pre-miniproAbollien was 8.4 kDa) as shown in Figs. 3a
Fig. 1 Homology modeling of miniproAbollien against miniproinsulin using DeepView/Swiss-Pdb Viewer. (a) Modeled miniproAbol-
lien (named Abollien in program) showing 0.000 A˚ root-mean-square deviation of the backbone atoms. (b) Miniproinsulin (named 1efeA
in program) showing 11.01 A˚ distance between B30 Thr and A1 Gly. (c) miniproAbollien (named Abollien in program) showing 11.01 A˚
distance between B30 Thr and A1 Gly.
Cloning and expression of a novel pre-miniproinsulin gene 667and 3b. Intensity of band observed on the gel for E. coli
JM109(DE3) was higher than E. coli BL21(DE3)pLysS.
Rapid screening and puriﬁcation of Pre-miniproAbollien
As shown in Fig. 4, ﬂow of cleared total cell lysate through Ni–
NTA column followed by washing and elution resulted in a
distinct band of Pre-miniproAbollien at between 7 and
15 kDa (nearer to 7 kDa). Flow through and washing showedcell proteins without any band at same size of Pre-minipro-
Abollien. First elution showed very high intensity band at
the same size of Pre-miniproAbollien and second elution
showed from one-third to half intensity of elution 1.
Immunological detection of Pre-miniproAbollien
After immunoblotting with polyclonal rabbit antibody against
human insulin, the nonstained bands of the expressed protein
Fig. 2a PCR analysis of expression construct extracted from
E. coli JM109. M: DNA 50 bp step ladder. L1: negative control
reaction. L2: PCR product of pET-24a(+) (positive control). L3:
PCR product of expression construct extracted from E. coli
JM109.
Fig. 2b PCR analysis of expression constructs extracted from
E. coli strains JM109(DE3) and BL21(DE3)pLysS. M: DNA
50 bp step ladder. L1: negative control reaction. L2: PCR product
of pET-24a(+) (positive control). L3: PCR product of expression
construct extracted from E. coli JM109(DE3). L4: PCR product of
expression construct extracted from E. coli BL21(DE3)pLysS.
Fig. 3a SDS–PAGE of the expressed Pre-miniproAbollien in
E. coli strain JM109(DE3). M: molecular weight marker. L1:
noninduced control sample. L2–6: samples taken at 1, 2, 4, 6 and
8 h after induction respectively.
Fig. 3b SDS–PAGE of the expressed Pre-miniproAbollien in
E. coli strain BL21(DE3)pLysS. M: Molecular weight marker. L1:
noninduced control sample. L2–5: samples taken at 2, 4, 6 and 8 h
after induction respectively.
668 A.A. Abolliel and H. Zedanshowed clear blots on the nitrocellulose membrane with inten-
sity increasing with concentration (Fig. 5, right). They were of
the same size of stained bands on the lane loaded with puriﬁed
Pre-miniproAbollien (Fig. 5, left).
Discussion
The present study describes the design and genetic expression
of new pre-miniproinsulin analogue (Pre-miniproAbollien) withpotential for use as a precursor for the production of recombi-
nant insulin. In the design of Pre-miniproAbollien, a 16-resi-
due pre area comprising the pentapeptide sequence (PSDKP)
of N-terminus of human TNF-a as a fusion area, a six histidine
residues spacer and a ﬁve peptide sequence ending by methio-
nine residue was used for the following reasons. The N-termi-
nal (PSDKP) sequence of human TNF-a is characterized by its
high-level expression and the characteristic b-sheet structure of
TNF-a has the property of protecting the protein from degra-
dation during expression [10,26]; it also increases the relative
proportion of miniproAbollien to the TNF-a moiety in the fu-
sion protein. In addition, the yield of E. coli JM109(DE3) and
E. coli BL21(DE3)pLysS expression cultures proved that the
N-terminal pentapeptide sequence (PSDKP) of human TNF-
Fig. 4 SDS–PAGE of puriﬁcation stages of pre-minipro-Abol-
lien. M: molecular weight marker. L1: total cell lysate. L2: ﬂow
through Ni–NTA column. L3: ﬁrst wash. L4: second wash. L5:
ﬁrst elution. L6: third elution. (L7): second elution.
Cloning and expression of a novel pre-miniproinsulin gene 669a protected the Pre-miniproAbollien from degradation as there
was no degradable protein in the gel even after 8 h of fermen-
tation as shown in Figs. 3a and 3b. The use of only 6 histidine
residues instead of 10 histidine residues used in other study [10]
further decreases the relative proportion of pre section in the
produced protein without affecting Ni2+ chelated-afﬁnity
puriﬁcation. The six histidine residues were sufﬁcient as the
Pre-miniproAbollien binds to Ni2+ in the Ni–NTA Spin Kit
and the elution contained a very high concentration of
Pre-miniproAbollien relevant to the starting cleared total cell
lysate (Fig. 4). To ease the chemical cleavage, a pentapeptideFig. 5 Nonstained (left) and stained (right) Western blots of puriﬁed
prestained Pierce blue protein molecular weight as protein marker. L1
(L2): 20 ll of puriﬁed Pre-minipro-Abollien expressed in JM109(D
JM109(DE3).ending by methionine residue was inserted between the
PSDKP sequence and the target protein as reported in a
previous study [10].
Recently, a number of miniproinsulins with various mini C-
peptides were produced to increase the folding efﬁciency of the
insulin precursor and the production yield of insulin [10,17,18].
Substitution of the 35-amino acid C-chain in human proin-
sulin with a shorter 9 residues as mini turn forming sequence in
the designed Pre-miniproAbollien was adopted for a number
of reasons: to increase the proportion of Abollien relative to
connecting chain comprising the b-turn and help turn forma-
tion in protein folding [10,27]. It also aids enzyme processing
required to release the native Abollien as most dibasic process-
ing sites were predicted to occur in a b-turn adjacent to a re-
gion of helix or b-sheet [28].
The strategy followed in designing of the insulin analogue
glargine was speciﬁcally directed toward a soluble formulation
at low pH but of reduced solubility relative to native insulin at
physiologic pH by the addition of two arginines to the C-ter-
minus of the B-chain. This change in combination with a gly-
cine substitution at A21 provides insulin with extended
duration of action [29]. In this study we added one lysine
and one arginine to the C-terminus of the B-chain in combina-
tion with glycine substitution at A21 and arginine substitution
at B29. This change has the potential of attenuating the IGF-1
receptor binding afﬁnity where concerns have been raised in
connection with the in vitro biochemical proﬁle of insulin glar-
gine speciﬁcally increased IGF-1 receptor afﬁnity and potential
for increased mitogenic potency [14–16].
The homology modeling of miniproAbollien against
miniproinsulin as a template (protein databank ﬁle 1efeA)
done by DeepView/Swiss-Pdb Viewer (Fig. 1) showed that
the distance between the a-carbons of the C-terminal of the
B-chain and the N-terminal of the A-chain was not altered
(11.01 A˚) and the root-mean-square deviation of the backbone
atoms (240 atoms) between the structures of modeled minipro-
Abollien and miniproinsulin was 0.000 A˚. Threading energy
was low on the changed residues. There were no residues mak-
ing clash generally or with backbone. It can be concluded thatPre-minipro-Abollien expressed in E. coli strain JM109(DE3). M:
: 10 ll of puriﬁed Pre-minipro-Abollien expressed in JM109 DE3.
E3). L3: 10 ll of puriﬁed Pre-minipro-Abollien expressed in
670 A.A. Abolliel and H. Zedanall homology modeling checks indicated that the small b turn
and the changes in the chains did not affect the three dimen-
sional structure of miniproinsulin.
The expression system was composed of three basic ele-
ments: a gene coding for the target protein, an expression vec-
tor to harbor the gene and a suitable host organism. The gene
was constructed with due consideration to the codon prefer-
ence of E. coli in order to allow high and stable expression
rates of the Pre-miniproAbollien gene in the host strain. The de-
signed gene was optimized then synthesized by DNA synthesis
technology. It was then sub-cloned to E. coli strain JM109 then
expressed in two E. coli strains JM109(DE3) and BL21(DE3)-
pLysS. Synthetic gene as an approach was chosen to bypass
hard mRNA isolation, go directly to exons without introns,
easy optimization and ﬁnally and most importantly to modify
sequence to the chosen analogue sequence. The success of
expression and 20% yield as appeared in SDS–PAGE
(Figs. 3a and 3b) showed that optimization was successful.
Success of sub-cloning strategy appears in the high yield of
pure nonnicked construct that yielded one sharp band repre-
senting neither truncated nor elongated cloned gene upon
ampliﬁcation by PCR and gel run (Figs. 2a and 2b).
Expression strategy depended on transformation of con-
struct in two E. coli strains JM109(DE3) and BL21(DE3)-
pLysS then expression under control of T7 lac promoter in
construct and maintaining catabolite repression condition by
glucose supplement in the media to aid the stability of eukary-
otic gene sequences and prevent the toxic effect reported for
insulin and specially miniproinsulin [30,31]. E. coli
JM109(DE3) and E. coli BL21(DE3)pLysS were chosen be-
cause of their properties of having rk and r

B respectively to
protect the construct. E. coli JM109(DE3) also contains lacIq
to inhibit transcription from lac promotor and to prevent leaks
of expressed protein before induction and decrease the toxicity
level of Pre-miniproAbollien after induction. E. coli
BL21(DE3)pLysS was chosen to do the same job but with
expression of T7 lysosymes that bind to T7 RNA polymerase.
Glucose fed in media prevents auto induction by cAMP [32].
Expression strategy showed good expression levels as shown
in Figs. 3a and 3b that bypass the apparent toxicity of Pre-
miniproAbollien noticed on the great suppression of cell
growth after induction compared to negative control of cul-
tures of the same strains transformed with plain pET-
24a(+). SDS–PAGE showed distinct bands without attached
bands with lower or higher size. This proved that there were
no truncated proteins due to incomplete translation or proteol-
ysis of protein. It proved also that there were not any proteins
with higher size as a result of inefﬁcient stop of transcription or
polymerization of the targeted protein. This conclusion was
supported by one band in the elution of puriﬁed Pre-minipro-
Abollien and no bands in the Ni–NTA column ﬂow through or
washing in SDS–PAGE (Fig. 4).
The identity of the protein amino acids were screened
for the six histidine residues in the pre area of Pre-
miniproAbollien as the Pre-miniproAbollien binds to Ni2+
in the Ni–NTA Spin Kit and the elutions contained a very
high concentration of Pre-miniproAbollien relevant to the
starting cleared total cell lysate as illustrated in Fig. 4. Study
using the western blot on the structural and immunological
similarity showed speciﬁc and quantity dependent interaction
between antibodies against human insulin and Pre-minipro-
Abollien (Fig. 5).Conclusions
A novel pre-miniproinsulin gene was synthesized, cloned and
expressed in E. coli. A distinct nontruncated protein having
the same immunological interaction of pure insulin and can
be puriﬁed with Ni–NTA technology was obtained.
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